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Abstract 
Murine myeloma SP2/0-Agl4 cells possess both nitrobenzylthioinosine (NBMPR)-sensitive and NBMPR-insensitive quilibrative 
uridine transport systems. No Na+-dependent uridine transport system was detected. The NBMPR-insensitive transport system is similarly 
insensitive to inhibition by dilazep and dipyridamole. Dose-response curve for the inhibition of equilibrative uridine transport by 
N-ethylmaleimide (NEM), a sulfhydryl reagent, in these cells was biphasic. About 30-40% of the uridine transport was inhibited by 
NEM at IC50 value of 0.15 mM. The other 60-70% of the transport activity remained insensitive to NEM at concentration ashigh as 3 
mM. The decrease in NBMPR-sensitive uridine transport in the presence of 0.3 mM NEM was due to a 3-fold decrease in transport 
affinity. Apparent K m values of 500 and 1600 p,M and Vma x values of 13 and 12 /zM/s were obtained for untreated and NEM-treated 
cells, respectively. NEM (0.3 mM) has little effect on the K m of NBMPR-insensitive transporter, with apparent K m values of 100 and 
110 /xM and Vma x values of 3.0 and 2.5 p,M/s for untreated and NEM-treated cells, respectively. High sensitivity of NBMPR-sensitive 
transporter to NEM inhibition was also observed in HL-60 and MCF-7 cells. Decrease in specific 3H-NBMPR equilibrium binding 
affinity in myeloma cells was observed after treatment with 0.3 mM NEM. Apparent K d values of 0.32 and 2.3 nM with Bma x values of 
48 000 and 44 000 sites/cell were obtained for untreated and NEM-treated cells, respectively. NBMPR, dilazep and dipyridamole at30 
/xM, and uridine at I0 mM failed to protect he NBMPR-sensitive transporter against NEM inhibition. It is possible that a critical 
sulfhydryl residue is closed to substrate binding/transporting site of the NBMPR-sensitive transporter. NEM, a sulfhydryl reagent 
containing an activated ouble bond, hinders the affinity of this transporter by forming a stable thiol ether bond with the reactive residue. 
Keywords: Uridine transport; Nucleoside transport; Myeloma; n-Ethylmaleimide 
1. Introduction 
Nucleosides cross cell membranes via a family of equi- 
librative transport systems which accept a variety of purine 
and pyrimidine nucleosides as substrates [1-4]. Subtypes 
of these transport systems can be distinguished by their 
differential sensitivities to inhibition by the S6-thiopurine 
derivatives nitrobenzylthioinosine (NBMPR) and nitroben- 
zylthio-guanosine (NBTGR). The NBMPR-sensitive trans- 
porter (NBMPR K i < 1 nM) has been studied extensively 
in many cell types, but the NBMPR-insensitive system 
(NBMPR K i > 1 /~M) has only come under investigative 
scrutiny recently. To date, many cell types were identified 
to possess both the NBMPR-sensitive and -insensitive 
* Corresponding author. Fax: +65 778-8161. 
0167-4889/95/$09.50 © 1995 Elsevier Science B.V. All rights reserved 
SSDI 01 67-4889(95)0008 1-X 
transporters [3,5-12]. The attributes of the NBMPR-insen- 
sitive transport system have not been as well defined as 
those of the NBMPR-sensitive system, primarily due to a 
lack of specific inhibitor for the NBMPR-insensitive mech- 
anism. Data showing the differences in these transport 
systems are mainly derived from transport kinetic, sub- 
strate specificity and inhibitor sensitivity studies. Since a 
direct comparison between these two transporters has not 
been made at molecular levels, it is not known whether the 
genetic distinction is at the level of the transporter protein 
itself, or due to differential expression of accessory pro- 
teins or post-translational processes. 
The effect of sulfhydryl reagents on nucleoside trans- 
port in mammalian cells has been somewhat controversial. 
Early studies have shown that incubation with organomer- 
curial reagents causes a marked inhibition of uridine up- 
take in a variety of cultured cells. Under the conditions of 
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these uptake measurements, however, substantial uridine 
metabolism occurred, making an unequivocal distinction 
between the effects on phosphorylation a d transport diffi- 
cult [13]. In some reports, indirect evidence suggested that 
the transport step rather than uridine phosphorylation was 
inhibited by sulfhydryl reagents [14], and such inhibition 
of uridine transport per se has been confirmed for Novikoff 
cells [15]. Incubation of uridine kinase-deficient Novikoff 
cells with p-chloromercuriphenyl sulfonate (pCMBS) 
greatly reduced uridine influx in these cells. In contrast, 
Belt [16,17] reported that uridine influx in wild-type and 
uridine kinase-deficient LI210 cells was little affected by 
incubation of the cells with pCMBS (IC50 > 400 /zM), 
except for the small NBMPR-insensitive component (about 
20% of total) which was strongly inhibited (IC50 < 25 
/xM). However, Plagemann and Wohlhueter [5,6] repeated 
the experiments using L1210 cells with results that do not 
agree with such a conclusion. 
In this study we have added to the controversy some- 
what by demonstrating that the NBMPR-sensitive trans- 
porter in murine myeloma, human promyelocytic leukemia 
HL-60, and human breast carcinoma MCF-7 cells is highly 
sensitive to N-ethylmaleimide (NEM) inhibition as com- 
pared to NBMPR-insensitive transporter. Studies using 
cells that possess either only NBMPR-sensitive (murine 
lymphoma EL-4) or NBMPR-insensitive (rat hepatoma 
Morris 7777) transport sys;tem also agree with this sugges- 
tion. NEM is a sulfhydryl reagent capable of forming 
stable thiol esters with the reactive sulfhydryl groups of 
proteins. This finding supports the notion that NBMPR- 
sensitive and -insensitive transporters are two structurally 
distinct ransporters ather than one transporter which man- 
ifests two conformations, of which only one is capable of 
binding NBMPR with high affinity, and, hence very sensi- 
tive to NBMPR inhibition. Thus high sensitivity to inhibi- 
tion by sulfhydryl reagents might be a specific property of 
NBMPR-sensitive quilibrative nucleoside transporter. 
2. Experimental procedures 
2.1. Cell culture 
Murine Sp2/0-Agl4 myeloma (ATCC CRL 1581), hu- 
man promyelocytic leukemia HL-60, rat hepatoma Morris 
7777, human breast carcinoma MCF-7, and murine lym- 
phoma EL-4 cells were maintained in continuous culture in 
RPMI 1640 medium (Gibco, Gaithersburg, MD) supple- 
mented with 10% heat-inactivated (50°C for 30 min) fetal 
bovine serum (Gibco) plus 50 units/ml of penicillin and 
50 /xg/ml of streptomycin (Gibco). 
2.2. [ 3H]Uridine transport 
Cells were harvested just before reaching confluency or 
plateau growth phase and prepared as described previously 
[18]. The uptake of [3H]uridine (final concentration of 50 
p~M, at 22-24°C) was initiated by simultaneously injecting 
20 /xl of cell suspension (8-9 × l0 s cells) and 40 /zl of 
[3H]uridine, using a Biohit Proline electronic pipettor (Bio- 
hit OY, Helsinki, Finland), into an 'oil-stop' tube [18]. 
After a time interval of 5 s, the cell mixture was separated 
from the transport medium by centrifugation using a Beck- 
man model E microcentrifuge. This time point was chosen 
as it fell within the initial linearity of the transport curve. 
In addition, greater than 95% of the intracellular metabo- 
lites were [3H]uridine as analyzed by HPLC (data not 
shown). In inhibition studies, test compounds and 
[3H]uridine were added simultaneously, with the exception 
of NBMPR, dipyridamole and dilazep that were preincu- 
bated with the cells for 15 min. The detailed composition 
of the final incubation medium is given in each figure 
legend. 'Time zero' values for transport, attributed to 
radioactivity trapped in the cell pellet, were determined by 
centrifuging a cell suspension (20 /zl) through a layer of 
[3H]uridine (40 /xl) layered over the oil in an 'oil-stop' 
tube. These values were subtracted from measurements of 
uptake by cells. The intracellular cell volume was calcu- 
lated in all experiments using 3H20 to determine total 
water space, and extracellular volume computed using 
[14C]sucrose as a measurement of extracellular space. For 
experimental purposes, equilibrative transport of uridine is 
defined as the difference between the intracellular concen- 
tration of [3H]uridine in cells suspended in Hanks' Na+-free 
(choline replacement) medium treated with or without 30 
/zM dipyridamole. 
2.3. [ ~H]NBMPR binding 
Equilibrium [3H]NBMPR binding assays were initiated 
by incubating 20 /xl of cell suspensions (8-9 × 105 cells) 
with graded concentrations of [3H]NBMPR (0.1-12 nM) 
in a total volume of 0.2 ml at 22-24°C, in the presence or 
absence of 20 /xM nitrobenzylthioguanosine (NBTGR) as 
a competing nonradioactive ligand. To ensure the studies 
were performed under true equilibrium conditions, a long 
incubation time of 60 min was used. Reactions were 
stopped by the 'oil-stop' method. Specific binding is de- 
fined as the difference in membrane content of 
[3H]NBMPR in the presence and absence of 20 /zM 
NBTGR. 
2.4. Irreversible inhibition by NEM 
Cells (1 × 108 cells/ml) were incubated with an equal 
volume of NEM. After one minute, a small aliquot (10-50 
/zl) of mercaptoethanol was added in a final concentration 
two-fold in excess over the NEM used. [3H]Uridine trans- 
port or [3H]NBMPR binding was measured immediately. 
Mercaptoethanol at concentrations a high as 60 mM has 
no adverse ffect on uridine transport. 
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2.5. Data analysis 
Kinetic constants of mediated transport of uridine (ap- 
parent K m and Vma x) and specific binding of NBMPR 
(apparent K d and Bma x) were  assessed by the use of 
non-linear squares fit of the Michaelis-Menten equation 
using the ENZFIT computer program [ 19]. 
2.6. Chemicals 
[5-3H]Uridine (20 Ci/mmol), [3H]NBMPR (25 
Ci/mmol) and []4C]sucrose (475 mCi/mmol) were pur- 
chased from New England Nuclear (Boston, MA). 3H20 
(18 /xCi/mmol) was purchased from Amersham (Arlin- 
gton Heights, IL). NEM, NBMPR, NBTGR, dilazep and 
dipyridamole were obtained from Sigma Chemical (St. 
Louis, MO). All other reagents were of analytical grade. 
3. Results 
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Fig. 2. Effects of NEM on equilibrative uridine transport by myeloma 
cells. Myeloma cells were treated with varying concentrations of NEM 
ranging from 0 to 30 mM for 1 min before the addition of 50 /xM 
[3H]uridine. The results are expressed as a percentage of the control 
influx rate (measured at 5 s uptake interval) versus the NEM concentra- 
tion. Data are representative of 4 separate xperiments. Values are the 
means _ S.E.M. of triplicate analyses. 
3.1. Uptake of uridine by myeloma cells 
The time course of [3H]uridine (50 /zM) uptake by 
murine myeloma treated with or without 30 /zM dipyri- 
damole and in the presence or absence of Na ÷ (choline 
replacement) is shown in Fig. 1. The uptake of uridine by 
myeloma was linear for about 5 s at 22°C. Therefore, in 
subsequent kinetic experiments, initial rates of uridine 
uptake were determined by measuring the cellular content 
of uridine after incubation intervals of 5 s at 22°C. Under 
these conditions, there was no significant metabolism of 
uridine (data not shown). Dipyridamole at 30/xM concen- 
tration almost completely inhibited the uptake of uridine. 
There is increasing evidence to suggest he presence of a 
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Fig. 1. Time course of uridine uptake by myeloma cells. Myeloma cells 
suspended in Na+-containing medium (0 ,  II) or Na+-free (choline 
replacement) medium (C), [] ) were preincubated with (11, [] ) or without 
(0 ,  C)) 30/.LM dipyridamole for 15 min before the addition of [3H]uridine 
at a final concentration of 50 /xM. Data are representative of four 
separate xperiments. Values are the means + S.E.M. of triplicate analy- 
ses. 
Na+-dependent nucleoside transport system in some mam- 
malian cells [18,20-27]. Thus, the effect of replacing Na ÷ 
with choline on the rate of uridine transport was investi- 
gated. The uptake of uridine in the presence of Na ÷ was 
identical to that observed with choline. Dipyridamole com- 
pletely inhibited the uptake of uridine under both condi- 
tions. Since the Na÷-dependent transport system generally 
has a higher transport affinity for substrates than the 
equilibrative transport systems [18], we had repeated the 
experiment using 5 /zM [3H]uridine and obtained similar 
results (data not shown). These findings suggest he ab- 
sence of Na+-dependent uridine transport system in murine 
myeloma cells. 
3.2. Effect of NEM on equilibrative transport of uridine by 
myeloma cells 
Murine myeloma cells were treated with varying con- 
centrations of NEM from 0 to 30 mM for 1 min prior 
transport assay. Fig. 2 shows the equilibrative transport of 
uridine was inhibited by NEM in an apparent biphasic 
manner. About 60-70% of the transport activity was inhib- 
ited by NEM with ICso value of 0.15 mM. The remaining 
30-40% of transport activity was gradually abolished by 
NEM at concentrations above 3.0 mM. It is very likely that 
murine myeloma cells possess two types of equilibrative 
transport systems which differ in their susceptibility to- 
wards molecular modification by NEM. 
It is evident hat most mammalian cells possess at least 
two types of equilibrative nucleoside transport systems 
[4,8,9,12,23,28-32]. These transport systems can generally 
be distinguished based on their sensitivity towards equili- 
brative nucleoside transport inhibitors such as NBMPR. 
Thus, to find out whether different ransport systems are 
present in these cells and determine their sensitivity to- 
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Fig. 3. Effects of NBMPR, di!~azep and dipyridamole on equilibrative 
uridine transport by myeloma cells. Myeloma cells, treated with (©) or 
without (O) 0.3 mM NEM for one minute, were preincubated with 
varying concentrations f NBMPR (panel a), dilazep (panel b), or dipyri- 
damole (panel c) for 15 min befiare the addition of 50/~M [3H]uridine in
the absence ofNa + (choline replacement). The results are expressed asa 
percentage of the control influx rate (measured at5 s uptake interval) 
versus the inhibitor concentration. Data are representative of at least five 
separate experiments. Values are the means_ S.E.M. of triplicate analy- 
ses. 
wards NEM inhibition, the dose response curves for inhibi- 
tion of uridine transport by NBMPR, dilazep and dipyri- 
damole in cells pretreated with or without 0.3 mM NEM 
were compared. Fig. 3 shows that the inhibition curves for 
all three transport inhibitors were biphasic. About 60% of 
the transport activity was inhibited by NBMPR (Fig. 3a), 
dilazep (Fig. 3b) and dipyridamole (Fig. 3c) with IC50 
values of 4, 100 and 2(10 nM, respectively. No further 
inhibition was observed until inhibitor concentrations ex- 
ceeded 1 /zM. The platean recurring in inhibition curves 
suggests the presence of two equilibrative uridine transport 
systems in murine myeloma cells that can be distinguished 
on the basis of their sensitivity to inhibition by either 
NBMPR, dilazep or dipyridamole. Thus, further charac- 
terization of these two transport systems were performed 
using cells treated with or without 100 nM NBMPR. 
Transport remaining in the presence of 100 nM NBMPR 
after being corrected for simple diffusion, was defined as 
NBMPR-insensitive transport, while the difference be- 
tween transport rates determined in the presence and ab- 
sence of 100 nM NBMPR represents NBMPR-sensitive 
transport. Fig. 3 also shows that cells pretreated with 0.3 
mM NEM lost the transport component hat is highly 
sensitive to the inhibitors. The inhibitor-insensitive trans- 
port component, however, was not affected by 0.3 mM 
NEM. The fact that the inhibitor-sensitive uridine transport 
component was abolished by 0.3 mM NEM, and that the 
relative proportion of NBMPR-sensitive transport obtained 
from the inhibitor dose-response curves (Fig. 3) was simi- 
lar to the relative proportion of transport activity that was 
highly sensitive to NEM (Fig. 2), suggest that the 
NBMPR-sensitive transport system may indeed be the 
NEM-sensitive component. In all experiments, reaction of 
NEM with the membrane was terminated by addition of 
mercaptoethanol in a concentration two-fold in excess of 
the NEM used prior transport assays. Control experiments 
showed that mercaptoethanol at concentrations a  high as 
60 mM had no apparent effect on uridine transport in 
NEM untreated cells (data not shown). 
3.3. Effect of NEM on the kinetics of NBMPR-sensitive and 
-insensitive transport of uridine by myeloma cells 
The concentration dependence of equilibrative 
NBMPR-sensitive and -insensitive uridine influx is shown 
in Fig. 4a. Apparent K m values of uridine influx for the 
NBMPR-sensitive and -insensitive components were 500 
_ 80 and 100 _ 20 /zM, respectively, with Vma x values of 
13 ___ 2 and 3.0 + 0.5 /zM/s,  respectively (means _ S.E. 
of 7 separate xperiments). After treatment with 0.3 mM 
NEM for 1 min, there was a 3-fold increase in K m value 
of uridine influx for NBMPR-sensitive component (ap- 
parent K m = 1600 + 450 /zM, n = 6) with little change in 
Vma x (Vma x= 12 _ 2 /.tM/s, n = 6). Transport kinetics for 
NBMPR-insensitive transport of uridine, however, was not 
significantly affected by 0.3 mM NEM (apparent K m = 
110 ___ 20 /zM, Vma x ---- 2.5 ___ 0.4 /.tM/s, n = 6). These re- 
suits suggested that the molecular modification of 
NBMPR-sensitive transporter protein by NEM hinders its 
ability to bind or transport the substrate ffectively. 
3.4. Effect of nucleosides on NBMPR-sensitive and -insen- 
sitive transport of uridine by myeloma cells 
Fig. 4a shows that the NBMPR-sensitive transport sys- 
tem has a lower transport affinity for uridine than the 
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Fig. 4. Effects of NEM on the kinetics of NBMPR-sensitive and -insensi- 
tive uridine transport systems. Myeloma cells were treated without (panel 
a) or with (panel b) 0.3 mM NEM for 1 min before starting the transport 
experiments. NBMPR-sensitive (0 )  and -insensitive (©) transport were 
determined using an uptake interval of 5 s with [3H]uridine concentra- 
tions ranging from 100 to 1000 /xM. NBMPR-insensitive transport was 
defined as transport in the presence of 100 nM NBMPR after subtracting 
the linear component determined in the presence of 30/~M dipyridamole. 
NBMPR-sensitive transport was defined as the difference between trans- 
port determined in the presence of 100 nM NBMPR and the total 
transport ate. Data for each panel are representative of at least 5 separate 
experiments. Values are the means + S,E.M. of triplicate analyses. For the 
data shown, the apparent K m values were 700-t-90 and 105+20 /xM, 
with Vma x values of 18+2 and 3.0__+0.6 /xM/s for NBMPR-sensitive 
and -insensitive transport systems, respectively. After treatment with 
NEM, the apparent K m values were 1600+200 and 120_+30 /xM, with 
Vma x values of 13_+3 and 2.5___0.5 /xM/s for NBMPR-sensitive and 
-insensitive transport systems, respectively. 
NBMPR-insensitive transport system. This finding is in 
contrast o some reports which showed opposite in other 
cell systems [5,9,11,29], but was similar to that of HL-60 
cells [12]. Thus, transport affinities of these two systems 
toward other physiological nucleosides were investigated 
by studying the effects of adenosine, inosine, guanosine, 
thymidine and cytidine 6n uridine influx by these two 
systems. Table 1 shows that uridine influx by NBMPR- 
sensitive and -insensitive components was inhibited by 
adenosine, guanosine and cytidine, with IC50 values of 
70-100, 540-630 and 510-670 /zM, respectively. Inter- 
estingly, inosine and thymidine were 4-fold more potent as 
an inhibitor of NBMPR-insensitive uridine transport than 
that of the NBMPR-sensitive transport. IC50 values were 
80-105 and 360-390 /xM for NBMPR-insensitive and 
-sensitive uridine transport, respectively. 
Table 1 
Effects of nucleosides on NBMPR-sensitive and -insensitive transport of 
uridine by myeloma cells 
Inhibitors 
ICs0 (/zM) 
NBMPR-sensitive NBMPR-insensitive 
Adenosine 100__+ 15 70_+ 10 
Inosine 390+ 100 105 + 10 
Guanosine 540+ 140 630+ 120 
Thymidine 360 + 80 80 + 10 
Cytidine 510_+ 30 670 + 130 
[3H]Uridine (final concentration 50 /zM) and nucleosides were added 
simultaneously to myeloma cells treated with or without NBMPR (100 
nM) in Na+-free (choline replacement) transport medium. After 5 s at 
22-24°C, uridine transport was terminated as described in Section 2. 
NBMPR-sensitive transport was defined as the difference between the 
total transport ates and the transport ates determined in the presence of 
100 nM NBMPR. NBMPR-insensitive transport was defined as transport 
in the presence of 100 nM NBMPR after subtracting the background 
determined in the presence of 30 /zM dipyridamole. Values are means + 
S.E.M. of at least 4 separate xperiments, each performed in triplicate. 
3.5. Effect of NEM on the kinetics of NBMPR equilibrium 
binding by myeloma cells 
To further demonstrate that the reduction in uridine 
influx by NBMPR-sensitive component is due to NEM-in- 
duced chemical modification on the carrier protein which 
subsequently affected the transport affinity, myeloma cells 
pretreated with or without 0.3 mM NEM for 1 min were 
assayed for the availability of high-affinity NBMPR bind- 
ing sites on the cell membranes. Fig. 5 shows that the K d 
value for NBMPR binding was changed significantly in 
response to NEM treatment. Shortly after 1 min of NEM 
exposure, the apparent K d value was 2.3 + 0.7 nM, as 
compared to 0.32_ 0.06 nM for untreated cells (n = 6). 
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Fig. 5. Effects of NEM on the kinetics of NBMPR equilibrium binding. 
Myeloma cells were treated with (O) or without (0 )  0.3 mM NEM for 1 
min before starting the [3H]NBMPR (0.1 to 12 nM) binding experiments. 
Data are representative of 5 separate xperiments. Values are the means 
+ S.E.M. of triplicate analyses. For the data shown, the apparent K d 
values were 1.9+0.4 and 0.16+0.02 nM, with Bma X values of 40000+ 
2600 and 41000+ 1000 sites/cell for NEM treated and untreated cells, 
respectively. 
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Fig. 6. Effects of NBMPR on equilibrative uridine transport by HL-60, 
MCF-7, Morris 7777, and EL-4 cells. HL-60 (Q), MCF-7 (©), Morris 
7777 (•),  and EL-4 ([]) cells w ere preincubated with varying concentra- 
tions of NBMPR for 15 min befi)re the addition of 50/zM [3H]uridine in
the absence of Na ÷ (choline replacement). The results are expressed asa 
percentage of the control influ): rate (measured at5 s uptake interval) 
versus the inhibitor concentration. Data are representative of 3-4 separate 
experiments. Values are the mezns + S.E.M. of triplicate analyses. 
However, the Bma x values of 44 000 +__ 4000 and 48 000 + 
6000 sites/cel l  for NEM treated and untreated cells, re- 
spectively, were not significantly different (n = 6). These 
results provide additional evidence that a critical 
disulfhydryl bond is located near or close to the substrate 
binding site of the NBMPR-sensitive transporter protein, 
where formation of disultlaydryl bonds with NEM affects 
the transport affinity of the carrier. 
3. 7. Effects of NEM on equilibrative transport of uridine 
by HL-60, MCF-7, Morris 7777, and EL-4 cells 
To demonstrate the differential sensitivity of these two 
equilibrative nucleoside transport systems to NEM is not 
unique to murine myeloma cells, we have repeated the 
same experiments with HL-60, MCF-7, Morris 7777 and 
EL-4 cells. HL-60 and MCF-7 cells possess both the 
NBMPR-sensitive and -insensitive uridine transport sys- 
tems. In these cells, the equilibrative transport of uridine 
was inhibited by NEM in a biphasic manner (Fig. 7) 
similar to that of myeloma cells (Fig. 2). About 75% of the 
transport activity was effectively abolished by NEM at a 
concentration of 0.3 mM, with IC50 values of 0.15 mM. 
The remaining 25% of the transport activity was gradually 
abolished by NEM at concentrations above 1 mM for 
HL-60 cells and above 3 mM for MCF-7 cells. In contrast 
to EL-4 and Morris 7777 cells, which possess only 
NBMPR-sensitive and -insensitive transport systems, re- 
spectively, both exhibit monophasic uridine transport 
curves in NEM dose-response experiments. The IC50 val- 
ues were approximately 0.1 and 1.5 mM for EL-4 and 
Morris 7777 cells, respectively. These results strongly 
suggested that the biphasic curve of total uridine transport 
observed in NEM dose-response experiments i a reflec- 
tion of the presence of two distinct equilibrative nucleoside 
transport systems in those cells. 
3.8. Effect of NEM on the kinetics of NBMPR-sensitive and 
-insensitive transport of uridine by HL-60 and MCF-7 
cells 
3.6. Demonstration of the presence or absence of 
NBMPR-sensitiue and -insensitive quilibratiue nucleoside 
transport systems in other cell types 
Table 2 shows the kinetics of NBMPR-sensitive and 
-insensitive uridine transport in HL-60 and MCF-7 cells 
It is possible that the effect of NEM on NBMPR-sensi- 
tive transporter is unique only to murine myeloma cells 
and not other cell types. As this cell line had not been 
previously analyzed and one could argue that these cells 
simply possess different nucleoside transport systems. To 
resolve this issue we have analyzed additional cell lines, 
some of them possessing; either an NBMPR-sensitive or 
-insensitive transport system, and examined the effect of 
NEM on equilibrative nucleoside transport systems under 
exactly the same conditions as used for the myeloma cells. 
Fig. 6 shows the dose response curves for inhibition of 
uridine transport by NBMPR in HL-60, MCF-7, Morris 
7777, and EL-4 cells. Beth HL-60 and MCF-7 cells pos- 
sess both NBMPR-sensitive and -insensitive transport sys- 
tems as judged by the biphasic inhibition curves. EL-4 and 
Morris 7777 cells, however, possess only NBMPR-sensi- 
tive and -insensitive transport systems, respectively. The 
equilibrative transport of uridine in Morris 7777 cells is 
also insensitive to dilazep and dipyridamole inhibition with 
IC50 values exceed 10 tzlVl (data not shown). 
lOO - T -~- - - - - - -~  I I  
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Fig. 7. Effects of HEM on cquilibrative uridine transport by HE-60, 
MCF-7, Morris 7777, and EL-4 cells. HL-60 (O), MCF-7 (O), Morris 
7777 (•) ,  and EL-4 ([]) cells suspended in Na+-free (choline replace- 
ment) medium were treated with varying concentrations of NEM ranging 
from 0 to 30 mM for 1 min before the addition of 50 /xM [3H]uridine. 
The results are expressed as a percentage of the control influx rate 
(measured at5 s uptake interval) versus the NEM concentration. Data are 
representative of 3-5 separate experiments. Values are the means +S.E.M. 
of triplicate analyses. 
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Table 2 
Effect of NEM on transport kinetics of NBMPR-sensitive and NBMPR- 
insensitive uridine transport systems in other cell types 
NBMPR-sensitive NBMPR-insensitive 
K m (/zM) Vma x(IxM/s) g m (/zM) Vma x(/zM/s) 
Untreated: 
HL-60 805:11 295:1 4305:160 23+5 
MCF-7 4305:70 205:3 3505:105 4.55:0.5 
NEM-treated: 
HL-60 _ a _ 1130+260 15+5 
MCF-7 - - 350 _ 95 5.1 _+ 0.5 
HL-60 and MCF-70 cells suspended in Na+-free (choline replacement) 
medium were treated with or without 0.3 mM NEM for 1 min before 
starting the transport assays. NBMPR-sensitive and -insensitive transport 
were determined using uptake interval of 5 s with [3H]uridine concentra- 
tion ranging from 50 to 1000 /xM. NBMPR-sensitive transport was 
defined as the difference between the total transport rates and the 
transport rates determined in the presence of 100 nM NBMPR. NBMPR- 
insensitive transport was defined as transport in the presence of 100 nM 
NBMPR after subtracting the linear component determined in the pres- 
ence of 30/xM dipyridamole. Values are means _+ S.E.M. of 4-8 separate 
experiments, each performed in triplicate. Kinetic constants for untreated 
HL-60 cells were obtained from Lee [12]. 
a Transport rates were too low for accurate determination f the parame- 
ters. 
after being treated with 0.3 mM NEM for 1 min. The 
apparent K m values for NBMPR-insensitive uridine trans- 
port was 1130 + 260 and 350 _ 95 /zM, with Vma x values 
of 15_  5 and 5.1 _+ 0.5 /xM/s for HL-60 and MCF-7 
cells, respectively. The transport kinetics for NBMPR-sen- 
sitive transport of uridine in both HL-60 and MCF-7 cells 
cannot be analyzed as little transport activity was left after 
NEM treatment. The apparent K m values of uridine influx 
in untreated HL-60 cells were 80 _+ 11 and 430 + 160 
/zM, with Vma x values of 29 ___ 1 and 23 + 5 /xM/s for 
NBMPR-sensitive and -insensitive transport systems, re- 
spectively [12]. For untreated MCF-7 cells, the apparent 
K m values of uridine influx were 430 __+ 70 and 350 _ 105 
/xM, with Vma x values of 20 + 3 and 4.5 + 0.5 /zM/s for 
NBMPR-sensitive and -insensitive transport systems, re- 
spectively. These results further demonstrated that the 
NBMPR-sensitive transport system may indeed be the 
NEM-sensitive component. 
4. Discussion 
Murine myeloma Sp2/0-Agl4, a cell line widely used 
in developing hybridomas ecreting specific monoclonal 
antibodies, possesses two distinct equilibrative uridine 
transport systems. These two transport systems can be 
distinguished based on their sensitivity toward equilibra- 
tive nucleoside transport inhibitors such as NBMPR, di- 
lazep and dipyridamole. Co-existence of NBMPR-sensitive 
and -insensitive quilibrative nucleoside transport systems 
is observed in most mammalian cells [5,8,9,12,17,29,33- 
36]. 
Aside from their differences in sensitivity towards nu- 
cleoside transport inhibitors, these two transport systems in 
myeloma cells also differed in their substrate specificities. 
Both transport systems have a broad substrate specificity, 
but the transport affinity for uridine of the NBMPR-sensi- 
tive system (K  m = 500 / zM)  was  approximately 5-fold 
less than the NBMPR-insensitive system (K  m = 100 /zM) .  
The affinity for adenosine, as determined from inhibition 
of uridine transport, was high for both transport systems 
(K~ = 70-100 /xM). In contrast, inosine and thymidine 
were more potent as inhibitors of NBMPR-insensitive 
uridine transport (K i = 80-100 /xM) than as inhibitors of 
NBMPR-sensitive uridine transport (K i = 360-600 /zM). 
These results indicate that inosine and thymidine together 
with uridine were preferentially transported by NBMPR- 
insensitive transport system. Both systems have low affini- 
ties for guanosine and cytidine (Ki = 500-700/xM). These 
results are very similar to those obtained from studies 
using undifferentiated HL-60 cells [12], with the exception 
that in HL-60 cells, uridine was preferentially transported 
by NBMPR-sensitive system (K  m = 80 ~M)  as compared 
to NBMPR-insensitive system (K  m - -430  /zM). However, 
the above results are not in agreement with those obtained 
from Chinese hamster ovary (CHO) cells [5], rat [29], 
guinea pig synaptosomes [9], and Ehrlich ascites cells [11], 
which showed that the transport affinities for most physio- 
logical nucleosides were generally higher in an NBMPR- 
sensitive system than in an NBMPR-insensitive system. In 
other studies using cultured cell lines such as mouse 
leukemia L1210 and P388, and Novikoff rat hepatoma, the 
substrate affinities for the two types of transport were 
indistinguishable [5,17]. The reason for this discrepancy is
unclear. It is important to note that most of these workers 
compared the kinetic constant for total uridine influx (fitted 
to a single component) with those measured in the pres- 
ence of NBMPR as suggested by Jarvis and Young [29]. 
Tissue variability may also give rise to the above discrep- 
ancy as both HL-60 and myeloma cells are of similar stem 
cell origin. Additional work is needed to determine this 
tissue specificity pertaining to other species and cell sys- 
tems. 
The molecular properties of these two transporters have 
not been compared and characterized fully due to a lack of 
specific ligand for the NBMPR-insensitive transporter. 
Thus, a search is needed for additional properties by which 
NBMPR-sensitive and -insensitive transporters can be fur- 
ther distinguished. In this study, we see a difference in the 
sensitivity of these two transport systems in myeloma, 
HL-60, and MCF-7 cells to NEM if the incubation with 
NEM is restricted to less than 5 min. NBMPR-sensitive 
transporter is consistently more sensitive to NEM inhibi- 
tion (IC50=0.10-0.15 mM) and NBMPR-insensitive 
transporter is less sensitive (IC50 = 1-5 mM). For cells 
that possess either only NBMPR-sensitive (EL-4) or 
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NBMPR-insensitive (Monis 7777) transport system also 
indicated that the NBMPR-sensitive system is more sensi- 
tive to NEM inhibition (IC50 =0.1  mM) than the 
NBMPR-insensitive system (IC50 = 1.5 raM). This differ- 
ence in susceptibility to NEM inhibition may reflect a 
difference in the primary structure of these transporter 
proteins. These findings, however, are in contrast o earlier 
reports which showed varied results towards organomercu- 
rial reagents, from no difference in the sensitivity of these 
two transport systems [5,6], to a high sensitivity in 
NBMPR-insensitive transport system compared to 
NBMPR-sensitive transport system [17,37]. The reason for 
this discrepancy is unclear and it may be due to different 
sulfhydryl reagents used. As the findings of Belt and Noel 
[37] clearly demonstrated, the NBMPR-insensitive nucleo- 
side transporter is 10-fold more sensitive to pCMBS than 
the NBMPR-sensitive transporter. However, when NEM 
was used, sensitivity of these transporters towards the 
reagent was reversed. In that study, the transport of uridine 
(100 /xM) in Walker 256 cells (NBMPR-insensitive) was 
inhibited by NEM with IC50 value of 250/zM, which was 
slightly higher than the value in $49 cells (NBMPR-sensi- 
tive), with IC50 value of 150 /zM. Furthermore, 
organomercurial reagents are capable of perturbing plasma 
membrane structure [37]. Plagemann and Wohlhueter [5] 
observed an increase in cell volume with 150-300 tzM 
p-hydroxymercuribenzenesulfonate (pHMBS). We were 
not able to repeat our experiments with pCMBS because 
our cells got fragile when the pCMBS concentration reaches 
200 /zM (data not shown). Thus, NEM could be a better 
sulfhydryl reagent for analyzing functional thiol group(s) 
on equilibrative nucleoside transport carriers in whole cells 
than the organomercurial reagents. The advantages can be 
summarized as (1) high selectivity for SH groups, (2) 
reaction with only certain accessible SH groups on the 
carriers, making it possible for specific transport inhibi- 
tions, and (3) reasonably good penetration i to cells due to 
the uncharged nature of the compound. 
The suggestion that the critical sulfhydryl group on the 
NBMPR-sensitive transporter protein is probably located 
near or close to but not on the substrate transporting/bind- 
ing site is derived from the observations that NBMPR, 
dilazep, dipyridamole at 30 /xM and uridine at 10 mM 
were incapable of protecting this sulfhydryl group from 
NEM modification (data not shown). The increase in K m 
value for NBMPR-sensitive uridine transport and K d value 
for NBMPR binding after NEM treatment, with little 
change in the respective Vma x and Bma x values, further 
support the inhibitory mechanism of NEM on the trans- 
porter protein. The location of this site cannot be deduced 
unequivocally from the plesent study as the membrane is 
generally considered permeable to NEM. 
The NBMPR-insensitive transporter, although less sen- 
sitive to NEM inhibition, can be inhibited at higher con- 
centrations of NEM or by prolonged exposure to NEM. 
This observation is in agreement with the general notion 
that sulfhydryl groups of enzymes display a considerable 
variation in their reactivity, ranging from unreactive, 
through several stages of sluggishness, to free and being 
immediately reactive. There may be some variations in the 
three-dimensional structure of the NBMPR-insensitive 
transporter protein such that the critical sulfhydryl group is 
located differently, creating a different microscopic envi- 
ronment, making the sulfhydryl group unreactive to exter- 
nal agents by interacting with a neighbouring roup or 
other functional groups. These may have resulted in the 
poor reactivity of the sulfhydryl group of this transporter 
protein in forming thiol ester(s) with NEM. 
In conclusion, the present results suggest that the 
NBMPR-sensitive equilibrative nucleoside transporter of 
myeloma, HL-60, MCF-7, Morris 7777, and EL-4 cells is 
highly sensitive to NEM as compared to the NBMPR-in- 
sensitive nucleoside transporter. It is possible that this 
property of NBMPR-sensitive equilibrative nucleoside 
transporter also applies to other cell types. 
Acknowledgements 
This work was supported by Research Grant RP910446 
and RP940314 from National University of Singapore. 
References 
[1] Paterson, A.R.P. and Cass, C.E. (1986) in Membrane Transport of 
Antineoplastic Agents (Goldman, I.D., ed.), pp. 309-329, Pergamon 
Press, Oxford. 
[2] Cass, C.E., Belt, J.A. and Paterson, A.R.P. (1987) Prog. Clin. 
Biochem. Res. 230, 13-40. 
[3] Plagemann, P.G.W., Wohlhueter, R.M. and Woffendin, C. (1988) 
Biochim. Biophys. Acta 947, 405-443. 
[4] Gati, W.P. and Paterson, A.R.P. (1989) in Red Blood Cell Mem- 
branes (Agre, P. and Parker, J.C., eds.), pp. 635-661, Marcel 
Dekker, New York. 
[5] Plagemann, P.G.W. and Wohlhueter, R.M. (1984) Biochim. Bio- 
phys. Acta 773, 39-52. 
[6] Plagemann, P.G.W. and Wohlhueter, R.M. (1984) Arch. Biochem. 
Biophys. 233, 489-500. 
[7] Paterson, A.R.P., Jakobs, E.S., Ng, C.Y.C., Odegard, R.D. and 
Adjei, A.A. (1987) in Topics and Perspectives in Adenosine Re- 
search (Gerlach, E. and Becker, B.F., eds.), pp. 89-101, Springer, 
Berlin. 
[8] Lee, C.W. and Jarvis, S.M. (1988) Biochem. J. 249, 557-564. 
[9] Lee, C.W. and Jarvis, S.M. (1988) Neurochem. Int. 12, 483-492. 
[10] Hammond, J.R. and Johnstone, R.M. (1989) Biochem. J. 262, 
109-118. 
[11] Hammond, J.R. (1991) J. Pharmacol. Exp. Ther. 259, 799-807. 
[12] Lee, C.W. (1994) Biochem. J. 300, 407-412. 
[13] Plagemann, P.G.W. and Wohlhueter, R.M. (1980) Curr. Top. Membr. 
Transp. 14, 225-230. 
[14] Plagemann, P.G.W. and Richey, D.P. (1974) Biochim. Biophys. 
Acta 344, 263-305. 
[15] Plagemann, P.G.W., Marz, R. and Wohlhueter, R.M. (1978) J. Cell. 
Physiol. 97, 49-72. 
[16] Belt, J.A. (1983) Biochem. Biophys. Res. Commun. 110, 417-423. 
[17] Belt, J.A. (1983) Mol. Pharrnacol. 24, 479-484. 
208 C.-W. Lee et aL / Biochimica et Biophysica Acta 1268 (1995) 200-208 
[18] Lee, C.W., Sokoloski, J.A., Sartorelli, A.C. and Handschumacher, 
R.E. (1991) Biochem. J. 274, 85-90. 
[19] Leatherbarrow, R.J. (1987) ENZFIT, Elsevier Biosoft, Cambridge. 
[20] Darnowski, J.W., Holdridge, C. and Handschumacher, R.E. (1987) 
Cancer Res. 47, 2614-2619. 
[21] Belt, J.A. and Noel, D.L. (1988) J. Biol. Chem. 263, 13819-13822. 
[22] Jarvis, S.M. (1989) Biochim. Biophys. Acta 979, 132-138. 
[23] Crawford, C., Ng, C.Y.C., Noel, D.L. and Belt, J.A. (1990) J. Biol. 
Chem. 265, 9732-9736. 
[24] Lee, C.W., Cheeseman, C.I. and Jarvis, S.M. (1988) Biochim. 
Biophys. Acta 942, 139-149. 
[25] Baer, H.P., Moorji, A. Ogbunude, P.O.J. and Serignese, V. (1992) 
Can. J. Physiol. Pharmacol. 70, 29-35. 
[26] Wu, X.C., Yuan, G., Brett, C.M., Hui, A.C. and Giacomini, K.M. 
(1992) J. Biol. Chem. 267, 8813-8818. 
[27] Doherty, A.J. and Jarvis, S.M. (1993) Biochim. Biophys. Acta 1147, 
214-222. 
[28] Plagemann, P.G.W. and Wohlhueter, R.M. (1985) Biochim. Bio- 
phys. Acta 816, 387-395. 
[29] Jarvis, S.M. and Young, J.D. (1986) J. Memb. Biol. 93, 1-10. 
[30] Marangos, P.J. and Decker, J. (1987) J. Neurochem. 48, 1231-1236. 
[31] Meckling-Gill, K.A. and Cass, C.E. (1992) Biochem. J. 282, 147- 
154. 
[32] Hammond, J.R. (1992) Biochem. J. 287, 431-436. 
[33] Eilam, Y. and Cabantchik, Z.I. (1977) J. Cell Physiol. 92, 185-202. 
[34] Bibi, O., Schwartz, J., Eilam, Y., Shohami, E. and Cabantchik, Z.I. 
(1978) J. Memb. Biol. 39, 159-183. 
[35] Heichal, O., Bibi, O., Katz, Y. and Cabantchik, Z.I. (1978) J. Memb. 
Biol. 39, 133-157. 
[36] Boumah, C.E., Hogue, D.L. and Cass, C.E. (1992) Biochem. J. 288, 
987-996. 
[37] Belt, J.A. and Noel, D.L. (1985) Biochem. J. 232, 681-688. 
